Alnylam Pharmaceuticals (ALNY) Shareholder Voloridge Investment Management Has Lifted Holding by $7.79 Million as Share Price Declined; Essex Financial Services Increased General Dynamicscorp (GD) Holding by $1.20 Million as Share Value Declined

June 14, 2018 - By Ellis Scott

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Logo

Essex Financial Services Inc increased its stake in General Dynamicscorp (GD) by 19.32% based on its latest 2018Q1 regulatory filing with the SEC. Essex Financial Services Inc bought 5,463 shares as the company’s stock declined 8.23% with the market. The institutional investor held 33,745 shares of the marine transportation company at the end of 2018Q1, valued at $7.45M, up from 28,282 at the end of the previous reported quarter. Essex Financial Services Inc who had been investing in General Dynamicscorp for a number of months, seems to be bullish on the $58.07B market cap company. The stock decreased 2.16% or $4.31 during the last trading session, reaching $195.51. About 1.59 million shares traded or 1.81% up from the average. General Dynamics Corporation (NYSE:GD) has risen 3.50% since June 14, 2017 and is uptrending. It has underperformed by 9.07% the S&P500. Some Historical GD News: 19/03/2018 – General Dynamics Shuns CSRA Price War as CACI Bids $7.2 Billion; 18/04/2018 – GENERAL DYNAMICS GETS INSCOM CONTRACT FOR IT NETWORKS; 25/04/2018 – GENERAL DYNAMICS CONCLUDES EARNINGS CONFERENCE CALL; 25/04/2018 – GENERAL DYNAMICS CEO SAYS TAX REFORM HELPING GULFSTREAM DEMAND; 02/05/2018 – General Dynamics Unit Jet Aviation Completes Acquisition of Hawker Pacific; 07/03/2018 – Sen. Sanders: Sanders, Warren, Merkley Demand General Dynamics Respect Its Workers; 20/03/2018 – General Dynamics Boosts Offer for CSRA; 25/04/2018 – GENERAL DYNAMICS: CUSTOMERS DELAYED DELIVERIES ON 2 AIRCRAFT; 17/04/2018 – INSIGHT-Arming the world: Inside Trump’s “Buy American” drive to expand weapons exports; 23/03/2018 – General Dynamics Awarded Contract to Synchronize U.S. Army Geospatial Technology Systems

Voloridge Investment Management Llc increased its stake in Alnylam Pharmaceuticals Inc (ALNY) by 503.11% based on its latest 2018Q1 regulatory filing with the SEC. Voloridge Investment Management Llc bought 65,470 shares as the company’s stock declined 18.72% with the market. The institutional investor held 78,483 shares of the health care company at the end of 2018Q1, valued at $9.35 million, up from 13,013 at the end of the previous reported quarter. Voloridge Investment Management Llc who had been investing in Alnylam Pharmaceuticals Inc for a number of months, seems to be bullish on the $10.76 billion market cap company. The stock increased 4.09% or $4.21 during the last trading session, reaching $107.07. About 462,918 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 43.86% since June 14, 2017 and is uptrending. It has outperformed by 31.29% the S&P500. Some Historical ALNY News: 15/05/2018 – ALNYLAM PHARMACEUTICALS INC SAYS ON MAY 12, CO’S BOARD EXPANDED SIZE OF BOARD FROM TEN TO ELEVEN – SEC FILING; 28/03/2018 – Alnylam Presents New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the 16th International Symposium on; 03/05/2018 – ALNYLAM 1Q ADJ LOSS/SHR $1.22; 03/05/2018 – Alnylam Achieves Alignment with FDA on Accelerated Development Path for Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1); 20/04/2018 – DICERNA PHARMACEUTICALS INC – DICERNA WILL DISMISS ALL COUNTERCLAIMS ASSOCIATED WITH ALNYLAM’S TRADE SECRET MISAPPROPRIATION LITIGATION; 24/04/2018 – Alnylam Pharmaceuticals: Patisiran Reduced Composite Rate of All-Cause Hospitalization and Mortality by About 50%, Relative to Placebo; 14/04/2018 – ALNYLAM PRESENTS NEW POSITIVE CLINICAL RESULTS FOR GIVOSIRAN,; 03/05/2018 – ALNYLAM PHARMACEUTICALS INC – COMPANY INTENDS TO INITIATE LUMASIRAN PHASE 3 STUDY IN MID-2018, WITH TOPLINE RESULTS EXPECTED IN 2019; 23/04/2018 – ALNYLAM GETS POS OPINION FOR ORPHAN DRUG IN EU ON ALN-TTRSC02; 20/04/2018 – Alnylam Reaches Settlement Agreement with Dicerna Pharmaceuticals Resolving Trade Secret Misappropriation and Other Pending

More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Seekingalpha.com which released: “Alnylam Pharmaceuticals Continues To Develop Options Outside Of Amyloidosis” on June 12, 2018, also Fool.com with their article: “Better Buy: Bellicum Pharmaceuticals, Inc. vs. Alnylam Pharmaceuticals, Inc.” published on June 03, 2018, Seekingalpha.com published: “Akcea And Ionis: What The Latest Regulatory Catalyst For Inotersen Foretells” on June 08, 2018. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Streetinsider.com and their article: “Alnylam Pharma (ALNY) Granted Orphan Drug Designation from FDA for ALN-TTRsc02” published on June 04, 2018 as well as Seekingalpha.com‘s news article titled: “Eidos Therapeutics files for initial public offering” with publication date: May 25, 2018.

Investors sentiment decreased to 1.4 in Q1 2018. Its down 0.63, from 2.03 in 2017Q4. It dived, as 25 investors sold ALNY shares while 67 reduced holdings. 43 funds opened positions while 86 raised stakes. 89.26 million shares or 1.02% less from 90.18 million shares in 2017Q4 were reported. Segall Bryant And Hamill Ltd Com invested in 0.01% or 2,000 shares. Lord Abbett And Limited Liability holds 297,210 shares. Voya Invest Mngmt Limited Liability Corporation holds 0.01% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) or 44,328 shares. Panagora Asset Mngmt Inc stated it has 0% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Guggenheim Capital Ltd Limited Liability Company holds 0.02% or 53,084 shares. Minnesota-based Ameriprise has invested 0% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Swiss Fincl Bank has invested 0.04% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Metropolitan Life Ins New York has 5,988 shares. Dodge Cox reported 0.45% stake. Hanseatic Mngmt Svcs Inc invested in 0.59% or 5,154 shares. Wexford Cap Limited Partnership accumulated 16,250 shares or 0.14% of the stock. Toronto Dominion Financial Bank reported 0% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Knott David M reported 249 shares. Rhumbline Advisers invested 0.02% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Benjamin F Edwards Incorporated holds 27 shares.

Since January 4, 2018, it had 0 insider purchases, and 11 insider sales for $39.55 million activity. Another trade for 36,745 shares valued at $4.84M was sold by Mason Michael. The insider Ausiello Dennis A sold $2.57 million. Shares for $2.24M were sold by SHARP PHILIP A on Tuesday, March 13. KEATING LAURIE sold $234,033 worth of stock. $1.50M worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares were sold by CLARKE JOHN K. Greenstreet Yvonne sold $985,958 worth of stock.

Among 24 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 17 have Buy rating, 1 Sell and 6 Hold. Therefore 71% are positive. Alnylam Pharmaceuticals had 108 analyst reports since August 7, 2015 according to SRatingsIntel. Needham maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Wednesday, November 16 with “Buy” rating. The rating was maintained by Stifel Nicolaus with “Hold” on Friday, August 11. The firm has “Buy” rating given on Thursday, October 6 by Needham. Jefferies maintained the shares of ALNY in report on Thursday, October 6 with “Buy” rating. The rating was maintained by BMO Capital Markets with “Buy” on Thursday, February 8. The rating was maintained by JMP Securities on Tuesday, April 3 with “Buy”. The firm has “Neutral” rating given on Thursday, September 29 by Janney Capital. Cowen & Co maintained the stock with “Buy” rating in Tuesday, July 11 report. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Overweight” rating by Barclays Capital on Wednesday, November 8. Goldman Sachs maintained it with “Neutral” rating and $34 target in Thursday, October 6 report.

Voloridge Investment Management Llc, which manages about $1.43 billion and $4.25B US Long portfolio, decreased its stake in National Instrs Corp (NASDAQ:NATI) by 16,327 shares to 24,843 shares, valued at $1.26 million in 2018Q1, according to the filing. It also reduced its holding in Skechers U S A Inc (NYSE:SKX) by 132,241 shares in the quarter, leaving it with 241,642 shares, and cut its stake in Ptc Inc (NASDAQ:PTC).

More news for General Dynamics Corporation (NYSE:GD) were recently published by: Fool.com, which released: “Is General Dynamics Corporation (GD) a Buy?” on June 01, 2018. Seekingalpha.com‘s article titled: “General Dynamics: Adequate Growth Potential” and published on May 23, 2018 is yet another important article.

Investors sentiment decreased to 0.88 in 2018 Q1. Its down 0.19, from 1.07 in 2017Q4. It is negative, as 52 investors sold GD shares while 361 reduced holdings. 100 funds opened positions while 263 raised stakes. 230.81 million shares or 0.50% more from 229.66 million shares in 2017Q4 were reported. Bartlett And Communication Ltd stated it has 160 shares or 0% of all its holdings. Horizon Kinetics Ltd Liability invested 0.01% of its portfolio in General Dynamics Corporation (NYSE:GD). Private Ocean reported 45 shares. Old Natl Bancorp In holds 6,770 shares or 0.08% of its portfolio. Toronto Dominion Retail Bank owns 189,779 shares for 0.09% of their portfolio. Richard Bernstein Advisors Llc holds 0.13% or 17,121 shares. Cetera Advisors Limited Com stated it has 5,016 shares or 0.07% of all its holdings. Howe & Rusling Inc reported 0% stake. White Pine Limited Liability Corporation reported 2,753 shares. Gotham Asset Management has 0.75% invested in General Dynamics Corporation (NYSE:GD). Teacher Retirement Of Texas holds 0.11% of its portfolio in General Dynamics Corporation (NYSE:GD) for 74,140 shares. 2,352 were accumulated by Boothbay Fund Mgmt Lc. Mariner Ltd Liability Com stated it has 4,128 shares. Fisher Asset Mgmt Limited Company has 0% invested in General Dynamics Corporation (NYSE:GD) for 14,412 shares. Waters Parkerson And Lc, a Louisiana-based fund reported 950 shares.

Essex Financial Services Inc, which manages about $2.52 billion and $509.95M US Long portfolio, decreased its stake in Thermo Fisherscientific Inc (NYSE:TMO) by 2,818 shares to 13,496 shares, valued at $2.79M in 2018Q1, according to the filing. It also reduced its holding in Southern Co (NYSE:SO) by 21,409 shares in the quarter, leaving it with 24,745 shares, and cut its stake in Exxon Mobil Corp (NYSE:XOM).

Among 22 analysts covering General Dynamics Corporation (NYSE:GD), 14 have Buy rating, 2 Sell and 6 Hold. Therefore 64% are positive. General Dynamics Corporation had 79 analyst reports since July 31, 2015 according to SRatingsIntel. The rating was maintained by RBC Capital Markets on Sunday, October 8 with “Buy”. The firm has “Hold” rating by Deutsche Bank given on Monday, December 5. The rating was maintained by Cowen & Co with “Buy” on Wednesday, July 26. The rating was maintained by Jefferies with “Buy” on Wednesday, April 19. The stock of General Dynamics Corporation (NYSE:GD) has “Overweight” rating given on Monday, November 30 by Barclays Capital. The firm earned “Neutral” rating on Wednesday, March 1 by Citigroup. The rating was upgraded by Bernstein to “Outperform” on Wednesday, August 10. On Thursday, January 25 the stock rating was maintained by Wells Fargo with “Outperform”. As per Tuesday, January 23, the company rating was maintained by RBC Capital Markets. Cowen & Co maintained General Dynamics Corporation (NYSE:GD) rating on Monday, September 18. Cowen & Co has “Buy” rating and $210.0 target.

General Dynamics Corporation (NYSE:GD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: